Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today that the company was awarded a Vaccine Industry Excellence Award in the category of "Best Early Stage Biotech" by a panel of judges composed of a broad selection of biotech industry stakeholders. The award was presented at the World Vaccine Congress being held April 19 - 22, 2010, in Washington, D.C.
The award citation highlighted Inovio's pioneering development of a DNA vaccine platform using electroporation delivery and its current clinical-stage DNA vaccine programs for influenza, HIV and cancer. The company is developing prophylactic and therapeutic vaccines targeting large and underserved disease areas. These include therapeutic cervical cancer and universal flu vaccines in Phase I clinical studies - both of which enjoy large market potential while serving a critical unmet medical need. Inovio is also developing HIV vaccines - both preventive and therapeutic - that are in multi-center Phase I trials.
Dr. J. Joseph Kim, President and CEO, said, "We greatly appreciate this recognition of Inovio's leadership and innovation in advancing the amazing protective capabilities provided by vaccines over the last century to potentially provide with our DNA vaccines better prevention and treatment of cancers and challenging infectious diseases. Our SynCon™ DNA vaccines delivered with our proprietary electroporation delivery systems have generated best-in-class immune responses and protection in preclinical animal models and have shown positive outcomes in our first reported human data. We look forward to the next stages of this exciting journey to commercialize this promising and important new generation of vaccines."
Pioneering vaccine strategy promises to outmaneuver antimicrobial resistance